928 related articles for article (PubMed ID: 17392405)
1. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
[TBL] [Abstract][Full Text] [Related]
2. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
3. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
Rami HK; Thompson M; Stemp G; Fell S; Jerman JC; Stevens AJ; Smart D; Sargent B; Sanderson D; Randall AD; Gunthorpe MJ; Davis JB
Bioorg Med Chem Lett; 2006 Jun; 16(12):3287-91. PubMed ID: 16580202
[TBL] [Abstract][Full Text] [Related]
4. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
El Kouhen R; Surowy CS; Bianchi BR; Neelands TR; McDonald HA; Niforatos W; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2005 Jul; 314(1):400-9. PubMed ID: 15837819
[TBL] [Abstract][Full Text] [Related]
5. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist.
Gunthorpe MJ; Rami HK; Jerman JC; Smart D; Gill CH; Soffin EM; Luis Hannan S; Lappin SC; Egerton J; Smith GD; Worby A; Howett L; Owen D; Nasir S; Davies CH; Thompson M; Wyman PA; Randall AD; Davis JB
Neuropharmacology; 2004 Jan; 46(1):133-49. PubMed ID: 14654105
[TBL] [Abstract][Full Text] [Related]
7. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia.
McDonald HA; Neelands TR; Kort M; Han P; Vos MH; Faltynek CR; Moreland RB; Puttfarcken PS
Eur J Pharmacol; 2008 Oct; 596(1-3):62-9. PubMed ID: 18755179
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning, functional characterization of the porcine transient receptor potential V1 (pTRPV1) and pharmacological comparison with endogenous pTRPV1.
Ohta T; Komatsu R; Imagawa T; Otsuguro K; Ito S
Biochem Pharmacol; 2005 Dec; 71(1-2):173-87. PubMed ID: 16288992
[TBL] [Abstract][Full Text] [Related]
9. Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8.
Weil A; Moore SE; Waite NJ; Randall A; Gunthorpe MJ
Mol Pharmacol; 2005 Aug; 68(2):518-27. PubMed ID: 15911692
[TBL] [Abstract][Full Text] [Related]
10. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
[TBL] [Abstract][Full Text] [Related]
11. Cloning and pharmacological characterization of mouse TRPV1.
Correll CC; Phelps PT; Anthes JC; Umland S; Greenfeder S
Neurosci Lett; 2004 Nov; 370(1):55-60. PubMed ID: 15489017
[TBL] [Abstract][Full Text] [Related]
12. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.
Gavva NR; Tamir R; Klionsky L; Norman MH; Louis JC; Wild KD; Treanor JJ
Mol Pharmacol; 2005 Dec; 68(6):1524-33. PubMed ID: 16135784
[TBL] [Abstract][Full Text] [Related]
13. Signaling mechanisms of down-regulation of voltage-activated Ca2+ channels by transient receptor potential vanilloid type 1 stimulation with olvanil in primary sensory neurons.
Wu ZZ; Chen SR; Pan HL
Neuroscience; 2006 Aug; 141(1):407-19. PubMed ID: 16678970
[TBL] [Abstract][Full Text] [Related]
14. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists.
Appendino G; Harrison S; De Petrocellis L; Daddario N; Bianchi F; Schiano Moriello A; Trevisani M; Benvenuti F; Geppetti P; Di Marzo V
Br J Pharmacol; 2003 Aug; 139(8):1417-24. PubMed ID: 12922928
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
16. Reducing and oxidizing agents sensitize heat-activated vanilloid receptor (TRPV1) current.
Susankova K; Tousova K; Vyklicky L; Teisinger J; Vlachova V
Mol Pharmacol; 2006 Jul; 70(1):383-94. PubMed ID: 16614139
[TBL] [Abstract][Full Text] [Related]
17. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
18. SA13353 (1-[2-(1-Adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea) inhibits TNF-alpha production through the activation of capsaicin-sensitive afferent neurons mediated via transient receptor potential vanilloid 1 in vivo.
Murai M; Tsuji F; Nose M; Seki I; Oki K; Setoguchi C; Suhara H; Sasano M; Aono H
Eur J Pharmacol; 2008 Jul; 588(2-3):309-15. PubMed ID: 18508045
[TBL] [Abstract][Full Text] [Related]
19. Functional changes in the vanilloid receptor subtype 1 channel during and after acute desensitization.
Novakova-Tousova K; Vyklicky L; Susankova K; Benedikt J; Samad A; Teisinger J; Vlachova V
Neuroscience; 2007 Oct; 149(1):144-54. PubMed ID: 17869438
[TBL] [Abstract][Full Text] [Related]
20. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.
Klionsky L; Tamir R; Holzinger B; Bi X; Talvenheimo J; Kim H; Martin F; Louis JC; Treanor JJ; Gavva NR
J Pharmacol Exp Ther; 2006 Oct; 319(1):192-8. PubMed ID: 16844842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
